Brazil health regulator lacks data needed to evaluate Sputnik V - (This is Money via NewsPoints Desk)

  • Brazil's health regulator Anvisa said in legal documents that it lacks the information necessary to evaluate the safety and efficacy of Russia's Sputnik V coronavirus vaccine, as reported in This is Money.

  • The documents were sent to Brazil's Supreme Court as part of an emergency request by the northeastern state of Maranhao to import the vaccine.

  • Anvisa lists various types of data that it lacks, including mass trial results and quality assurances, adding it does not have sufficient information to carry out a "positive benefit-versus-risk analysis" of Sputnik V.

To read more NewsPoints articles, click here.